tiprankstipranks
Advertisement
Advertisement
3 ‘Strong Buy’ Stocks to Buy in Today’s Volatile Market, 2/23/2026, According to Top Analysts
PremiumMarket News3 ‘Strong Buy’ Stocks to Buy in Today’s Volatile Market, 2/23/2026, According to Top Analysts
1M ago
Spyre Therapeutics: Rich 12-Month Catalyst Calendar and Differentiated IBD Portfolio Support Buy Rating
Premium
Ratings
Spyre Therapeutics: Rich 12-Month Catalyst Calendar and Differentiated IBD Portfolio Support Buy Rating
1M ago
Spyre Therapeutics: Accelerating Clinical Momentum, Validated Combination Strategy, and Strong Cash Runway Support Buy Rating
Premium
Ratings
Spyre Therapeutics: Accelerating Clinical Momentum, Validated Combination Strategy, and Strong Cash Runway Support Buy Rating
1M ago
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
PremiumCompany AnnouncementsSpyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
3M ago
Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
Premium
The Fly
Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
3M ago
Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
Premium
Ratings
Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
3M ago
Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
PremiumRatingsBuy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
4M ago
Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
Premium
The Fly
Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
4M ago
3 Best Stocks to Buy Now, 12/1/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 12/1/2025, According to Top Analysts
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100